KRYS Quote, Financials, Valuation and Earnings

Cormedix has a net margin of 40.52% compared to Krystal Biotech's net margin of 52.82%. Krystal Biotech's return on equity of 13.91% beat Cormedix's return on equity of 23.7%.

Krystal Biotech has a consensus price target of $208.00, signalling upside risk potential of 38.59%. On the other hand Cormedix has an analysts' consensus of $19.00 which suggests that it could grow by 70.71%. Given that Cormedix has higher upside potential than Krystal Biotech, analysts believe Cormedix is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.675, which suggesting that the stock is 32.514% less volatile than S&P 500. In comparison Cormedix has a beta of 1.581, suggesting its more volatile than the S&P 500 by 58.146%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $88.2M, which are larger than Cormedix quarterly revenues of $39.1M. Krystal Biotech's net income of $35.7M is higher than Cormedix's net income of $20.6M. Notably, Krystal Biotech's price-to-earnings ratio is 36.08x while Cormedix's PE ratio is 50.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 13.43x versus 8.32x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of 40.52% compared to Krystal Biotech's net margin of 73.68%. Krystal Biotech's return on equity of 13.91% beat PTC Therapeutics's return on equity of --.

Krystal Biotech has a consensus price target of $208.00, signalling upside risk potential of 38.59%. On the other hand PTC Therapeutics has an analysts' consensus of $62.81 which suggests that it could grow by 30.48%. Given that Krystal Biotech has higher upside potential than PTC Therapeutics, analysts believe Krystal Biotech is more attractive than PTC Therapeutics.

Krystal Biotech has a beta of 0.675, which suggesting that the stock is 32.514% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.501, suggesting its less volatile than the S&P 500 by 49.905%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $88.2M, which are smaller than PTC Therapeutics quarterly revenues of $1.2B. Krystal Biotech's net income of $35.7M is lower than PTC Therapeutics's net income of $866.6M. Notably, Krystal Biotech's price-to-earnings ratio is 36.08x while PTC Therapeutics's PE ratio is 7.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 13.43x versus 2.15x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rigel Pharmaceuticals has a net margin of 40.52% compared to Krystal Biotech's net margin of 21.46%. Krystal Biotech's return on equity of 13.91% beat Rigel Pharmaceuticals's return on equity of --.

Krystal Biotech has a consensus price target of $208.00, signalling upside risk potential of 38.59%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 75.01%. Given that Rigel Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Rigel Pharmaceuticals is more attractive than Krystal Biotech.

Krystal Biotech has a beta of 0.675, which suggesting that the stock is 32.514% less volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.398%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $88.2M, which are larger than Rigel Pharmaceuticals quarterly revenues of $53.3M. Krystal Biotech's net income of $35.7M is higher than Rigel Pharmaceuticals's net income of $11.4M. Notably, Krystal Biotech's price-to-earnings ratio is 36.08x while Rigel Pharmaceuticals's PE ratio is 9.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 13.43x versus 1.69x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of 40.52% compared to Krystal Biotech's net margin of 4.19%. Krystal Biotech's return on equity of 13.91% beat TG Therapeutics's return on equity of 19.78%.

Krystal Biotech has a consensus price target of $208.00, signalling upside risk potential of 38.59%. On the other hand TG Therapeutics has an analysts' consensus of $40.50 which suggests that it could grow by 4.27%. Given that Krystal Biotech has higher upside potential than TG Therapeutics, analysts believe Krystal Biotech is more attractive than TG Therapeutics.

Krystal Biotech has a beta of 0.675, which suggesting that the stock is 32.514% less volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Krystal Biotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Krystal Biotech pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Krystal Biotech quarterly revenues are $88.2M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Krystal Biotech's net income of $35.7M is higher than TG Therapeutics's net income of $5.1M. Notably, Krystal Biotech's price-to-earnings ratio is 36.08x while TG Therapeutics's PE ratio is 161.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Krystal Biotech is 13.43x versus 16.16x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.